868 results on '"Verbeek, Marcel M."'
Search Results
2. Temporal Ordering of Biomarkers in Dutch-Type Hereditary Cerebral Amyloid Angiopathy
3. Decreased ratios of matrix metalloproteinases to tissue-type inhibitors in cerebrospinal fluid in sporadic and hereditary cerebral amyloid angiopathy
4. An emerging biomarker for dopaminergic cell loss
5. Correction: Serum and cerebrospinal fluid neurofilament light chain and glial fibrillary acid protein levels in early and advanced stages of cerebral amyloid angiopathy
6. Altered brain expression and cerebrospinal fluid levels of TIMP4 in cerebral amyloid angiopathy
7. Proximity extension assay in cerebrospinal fluid identifies neurofilament light chain as biomarker of neurodegeneration in sporadic cerebral amyloid angiopathy
8. The relation of a cerebrospinal fluid profile associated with Alzheimer’s disease with cognitive function and neuropsychiatric symptoms in sporadic cerebral amyloid angiopathy
9. Serum and cerebrospinal fluid neurofilament light chain and glial fibrillary acid protein levels in early and advanced stages of cerebral amyloid Angiopathy
10. Neuropsychiatric symptoms with focus on apathy and irritability in sporadic and hereditary cerebral amyloid angiopathy
11. Cerebrospinal fluid shotgun proteomics identifies distinct proteomic patterns in cerebral amyloid angiopathy rodent models and human patients
12. Factors associated with mortality in early stages of parkinsonism
13. Mechanisms of peripheral levodopa resistance in Parkinson’s disease
14. Profiling amyloid‐β peptides as biomarkers for cerebral amyloid angiopathy.
15. Divergent Associations of Slow‐Wave Sleep versus Rapid Eye Movement Sleep with Plasma Amyloid‐Beta.
16. The novel P330L pathogenic variant of aromatic amino acid decarboxylase maps on the catalytic flexible loop underlying its crucial role
17. Succinic semialdehyde dehydrogenase deficiency in mice and in humans: An untargeted metabolomics perspective.
18. Peripheral decarboxylase inhibitors paradoxically induce aromatic L-amino acid decarboxylase
19. Correction to: Cerebrospinal fluid levels of the neurotrophic factor neuroleukin are increased in early Alzheimer’s disease, but not in cerebral amyloid angiopathy
20. Cerebrospinal fluid levels of the neurotrophic factor neuroleukin are increased in early Alzheimer’s disease, but not in cerebral amyloid angiopathy
21. Identification of cerebrospinal fluid biomarkers for parkinsonism using a proteomics approach
22. MFG-E8 (LACTADHERIN): a novel marker associated with cerebral amyloid angiopathy
23. Cerebrospinal fluid myelin basic protein is elevated in multiple system atrophy
24. Linking APOE-ε4, blood-brain barrier dysfunction, and inflammation to Alzheimer's pathology
25. Reduced Influence of apoE on Aβ43 Aggregation and Reduced Vascular Aβ43 Toxicity as Compared with Aβ40 and Aβ42
26. Valuing biomarker diagnostics for dementia care: enhancing the reflection of patients, their care-givers and members of the wider public
27. Longitudinal cerebrospinal fluid biomarker trajectories along the Alzheimer's disease continuum in the BIOMARKAPD study
28. Autoimmune Encephalitis Resembling Dementia Syndromes
29. The impact of preanalytical variables on measuring cerebrospinal fluid biomarkers for Alzheimer's disease diagnosis: A review
30. Prevalence of the apolipoprotein E ε4 allele in amyloid β positive subjects across the spectrum of Alzheimer's disease
31. Cerebral tryptophan metabolism and outcome of tuberculous meningitis: an observational cohort study
32. Cerebrospinal fluid monocyte chemoattractant protein 1 correlates with progression of Parkinson’s disease
33. Cerebrospinal Fluid Galectin-1 Levels Discriminate Patients with Parkinsonism from Controls
34. Reader response: Blood NfL: A biomarker for disease severity and progression in Parkinson disease
35. Disturbed balance in the expression of MMP9 and TIMP3 in cerebral amyloid angiopathy-related intracerebral haemorrhage
36. Inflammation biomarker discovery in Parkinson’s disease and atypical parkinsonisms
37. Aβ43 in human Alzheimer’s disease: effects of active Aβ42 immunization
38. C-Reactive Protein, Plasma Amyloid-β Levels, and Their Interaction With Magnetic Resonance Imaging Markers
39. A multifunctional ELISA to measure oxidised proteins: oxPin1 in Alzheimer's brain as an example
40. Validation of a quantitative cerebrospinal fluid alpha-synuclein assay in a European-wide interlaboratory study
41. Serum NFL discriminates Parkinson disease from atypical parkinsonisms
42. Activation of TNF Receptor 2 Improves Synaptic Plasticity and Enhances Amyloid-β Clearance in an Alzheimer's Disease Mouse Model with Humanized TNF Receptor 2.
43. Plasma amyloid beta 42 is a biomarker for patients with hereditary, but not sporadic, cerebral amyloid angiopathy.
44. MicroRNAs in Cerebrospinal Fluid as Potential Biomarkers for Parkinson’s Disease and Multiple System Atrophy
45. Time trends in demographic characteristics of participants and outcome measures in Parkinson’s disease research: A 19-year single-center experience
46. Addition of MHPG to Alzheimer's disease biomarkers improves differentiation of dementia with Lewy bodies from Alzheimer's disease but not other dementias
47. MicroRNAs in Alzheimer's disease: differential expression in hippocampus and cell-free cerebrospinal fluid
48. An attenuated, adult case of AADC deficiency demonstrated by protein characterization
49. Mutations in CYB561 Causing a Novel Orthostatic Hypotension Syndrome
50. Multicenter evaluation of neurofilaments in early symptom onset amyotrophic lateral sclerosis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.